Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Jun 30, 2025 | Clark Street Value | - | -3.6% | ACR, ATHA, CKX, CMCT, CRGX, EHAB, EPIX, GRBK, HLVX, HMST, IGT, IKNA, IOR, ME, MREO, MURA, NSTS, PARR, RPTX, SEG, SHCO, THRD | Banking, Biotechnology, REITs, small caps, special situations, value | Manager holds extensive broken biotech basket including companies that have halted development and are pursuing strategic alternatives or liquidations. These biotechs trade at significant discounts to net cash with potential for Tang-style buyouts or liquidations. | IGT EHAB SHCO NSTS IOR CKX THRD RPTX MURA EPIX ATHA |
View |
| 2025 Q2 | Jun 30, 2025 | Signia Capital Management | 19.2% | 6.9% | ARHS, FTK, GLDD, HMST, HZO, METC, OPRT, ORN, PGNY, RRGB, SEI, TGB, TRC, VPG | AI, Bottom-up, Copper, Microcap, Robotics, small caps, value | North American copper producer Taseko Mines delivered strong performance driven by rising copper prices and company-specific developments. The Florence mine in Arizona is expected to begin production in mid-2026, nearly doubling Taseko's copper output from 120 million pounds in 2025 to 200 million pounds by 2027. With copper prices above $5 per pound, TGB is well positioned to grow earnings and cash flow. | TGB VPG TGB VPG |
View |
| 2024 Q4 | Dec 31, 2024 | Clark Street Value | - | -6.4% | ACR, ALVR, ATHA, AVTE, CKX, CMCT, EHAB, ENZ, EPIX, GRBK, HHH, HLVX, HMST, IKNA, INBX, LMNR, MREO, PARR, SEG | Biotechnology, Liquidations, M&A, real estate, special situations, spinoffs, value | Multiple SPAC-related investments including reverse merger situations where biotech companies are merging with private entities. These transactions often include special dividends, CVRs, and oversubscribed PIPEs that can create value for existing shareholders. | View | |
| 2023 Q4 | Dec 29, 2023 | Clark Street Value | - | 38.5% | ACI, AVRO, BANC, CKX, CYT, ELYM, ESPR, FHN, FIXX, GRPH, HMST, KNTE, MBI, MRC, MREO, PIRS, RPHM, SAVE, SIOX, THRX | Biotechnology, M&A, real estate, Regional Banks, small caps, special situations, value | Manager holds a substantial broken biotech basket focused on companies undergoing strategic alternatives including reverse mergers, liquidations, and takeover offers. Multiple biotech positions are trading below net cash with potential value from IP assets and CVRs. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| No pitches found. | |||||||||
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||